Literature DB >> 12200815

Factors influencing erythropoietin compliance in peritoneal dialysis patients.

Lori D Wazny1, Biljana B Stojimirovic, Paul Heidenheim, Peter G Blake.   

Abstract

BACKGROUND: Peritoneal dialysis patients who manage their own therapy with subcutaneous erythropoietin (EPO) may be at risk for noncompliance. The objectives of this study were to examine the rate of noncompliance and to investigate the factors that are associated with patient noncompliance with the prescribed EPO regimen.
METHODS: A multiple-choice questionnaire was mailed to eligible patients, and a review of pharmacy records was conducted for EPO dates of refill. Noncompliance was defined as less than 90% use of the prescribed dose either by pharmacy record review or missed injections on the questionnaire.
RESULTS: Of 55 eligible patients, 54 completed the questionnaire. The overall rate of noncompliance was 35%. Patients who were noncompliant were younger (P = 0.005), had fewer comorbidities (P = 0.050), had been on EPO therapy longer (P = 0.011), were more likely to have completed postsecondary education (P = 0.011), and were more likely to admit to missed peritoneal dialysis exchanges (P = 0.011). On multiple regression analysis, the independent predictors of noncompliance, in order of importance, were missing dialysis exchanges, completion of postsecondary education, and younger age.
CONCLUSION: These findings suggest that noncompliance with EPO injections is relatively common among peritoneal dialysis patients. The independent predictors of noncompliance were missing dialysis exchanges, completion of postsecondary education, and younger age. Further studies are needed to determine if specific interventions targeting this group of patients can affect compliance. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200815     DOI: 10.1053/ajkd.2002.34925

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

Review 1.  Resistance to erythropoietin-stimulating agents: etiology, evaluation, and therapeutic considerations.

Authors:  Oluwatoyin Bamgbola
Journal:  Pediatr Nephrol       Date:  2011-03-20       Impact factor: 3.714

2.  Assessing a pharmacist-run anaemia educational programme for patients with chronic renal insufficiency.

Authors:  B Allenet; C Chen; T Romanet; P Vialtel; J Calop
Journal:  Pharm World Sci       Date:  2007-02

3.  Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis.

Authors:  Raja Zabaneh; Simon D Roger; Mohamed El-Shahawy; Michael Roppolo; Grant Runyan; Janet O'Neil; Ping Qiu
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

Review 4.  Continuous ambulatory peritoneal dialysis: perspectives on patient selection in low- to middle-income countries.

Authors:  Nicola Wearne; Kajiru Kilonzo; Emmanuel Effa; Bianca Davidson; Peter Nourse; Udeme Ekrikpo; Ikechi G Okpechi
Journal:  Int J Nephrol Renovasc Dis       Date:  2017-01-04

Review 5.  The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee.

Authors:  Cornelis H Schröder
Journal:  Pediatr Nephrol       Date:  2003-05-15       Impact factor: 3.714

6.  Non-adherence in patients on peritoneal dialysis: a systematic review.

Authors:  Konstadina Griva; Alden Yuanhong Lai; Haikel Asyraf Lim; Zhenli Yu; Marjorie Wai Yin Foo; Stanton P Newman
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.